An update from Diamedica Therapeutics ( (DMAC) ) is now available.
On February 20, 2025, DiaMedica Therapeutics appointed Daniel J. O’Connor to its Board of Directors, recognizing his extensive experience in the biopharmaceutical industry. O’Connor’s leadership background, including his role in the acquisition of Ambrx Biopharma by Johnson & Johnson, positions him as a valuable asset to DiaMedica as it continues to advance its pipeline of treatments for acute ischemic stroke and preeclampsia.
More about Diamedica Therapeutics
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for acute ischemic stroke and preeclampsia. Their lead candidate, DM199, is a recombinant form of the KLK1 protein, which is used in Asia for treating ischemic diseases.
YTD Price Performance: 18.15%
Average Trading Volume: 97,123
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $278.4M
For a thorough assessment of DMAC stock, go to TipRanks’ Stock Analysis page.